{"id":37449,"date":"2025-07-16T16:46:29","date_gmt":"2025-07-16T08:46:29","guid":{"rendered":"https:\/\/flcube.com\/?p=37449"},"modified":"2025-07-16T16:46:30","modified_gmt":"2025-07-16T08:46:30","slug":"danahers-cytiva-collaborates-with-correctsequence-on-gene-therapy-lnp-delivery-system","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37449","title":{"rendered":"Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System"},"content":{"rendered":"\n

US-based science and tech services giant Danaher Corporation (NYSE: DHR<\/a>) announced an ongoing collaboration between its unit Cytiva and Shanghai-based gene editing technology provider CorrectSequence Therapeutics. Together, they are developing an innovative process solution for gene therapy using lipid nanoparticle (LNP) delivery systems. This partnership aims to drive breakthroughs in treating genetic diseases and marks Danaher’s first Beacon Project with a Chinese biotech firm.<\/p>\n\n\n\n

Cytiva’s Fast Trak Center<\/strong>
Cytiva’s Fast Trak center in Shanghai’s Zhangjiang area is pivotal to this collaboration. It provides core technical support, including process development and scalable manufacturing for gene editing therapies. The center is home to Asia’s largest modular bioprocessing workstation and offers comprehensive services from nucleic acid drug preparation to cGMP-scale production.<\/p>\n\n\n\n

Proven Track Record<\/strong>
The Fast Trak center has successfully completed numerous gene therapy process development projects. Its expertise and state-of-the-art facilities are key to advancing the development of gene therapies, which hold great promise for treating genetic diseases.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between…<\/p>\n","protected":false},"author":1,"featured_media":37450,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3757,3454,535,66,1265],"class_list":["post-37449","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-correctsequence-therapeutics","tag-cytiva","tag-danaher","tag-gene-therapy","tag-nyse-dhr"],"yoast_head":"\nDanaher's Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between its unit Cytiva and Shanghai-based gene editing technology provider CorrectSequence Therapeutics. Together, they are developing an innovative process solution for gene therapy using lipid nanoparticle (LNP) delivery systems. This partnership aims to drive breakthroughs in treating genetic diseases and marks Danaher's first Beacon Project with a Chinese biotech firm.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37449\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Danaher's Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System\" \/>\n<meta property=\"og:description\" content=\"US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between its unit Cytiva and Shanghai-based gene editing technology provider CorrectSequence Therapeutics. Together, they are developing an innovative process solution for gene therapy using lipid nanoparticle (LNP) delivery systems. This partnership aims to drive breakthroughs in treating genetic diseases and marks Danaher's first Beacon Project with a Chinese biotech firm.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37449\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-16T08:46:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-16T08:46:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1609.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37449#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37449\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System\",\"datePublished\":\"2025-07-16T08:46:29+00:00\",\"dateModified\":\"2025-07-16T08:46:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37449\"},\"wordCount\":177,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37449#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1609.webp\",\"keywords\":[\"CorrectSequence Therapeutics\",\"Cytiva\",\"Danaher\",\"Gene therapy\",\"NYSE: DHR\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37449#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37449\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37449\",\"name\":\"Danaher's Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37449#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37449#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1609.webp\",\"datePublished\":\"2025-07-16T08:46:29+00:00\",\"dateModified\":\"2025-07-16T08:46:30+00:00\",\"description\":\"US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between its unit Cytiva and Shanghai-based gene editing technology provider CorrectSequence Therapeutics. Together, they are developing an innovative process solution for gene therapy using lipid nanoparticle (LNP) delivery systems. This partnership aims to drive breakthroughs in treating genetic diseases and marks Danaher's first Beacon Project with a Chinese biotech firm.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37449#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37449\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37449#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1609.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1609.webp\",\"width\":1080,\"height\":608,\"caption\":\"Danaher's Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37449#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Danaher's Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System - Insight, China's Pharmaceutical Industry","description":"US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between its unit Cytiva and Shanghai-based gene editing technology provider CorrectSequence Therapeutics. Together, they are developing an innovative process solution for gene therapy using lipid nanoparticle (LNP) delivery systems. This partnership aims to drive breakthroughs in treating genetic diseases and marks Danaher's first Beacon Project with a Chinese biotech firm.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37449","og_locale":"en_US","og_type":"article","og_title":"Danaher's Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System","og_description":"US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between its unit Cytiva and Shanghai-based gene editing technology provider CorrectSequence Therapeutics. Together, they are developing an innovative process solution for gene therapy using lipid nanoparticle (LNP) delivery systems. This partnership aims to drive breakthroughs in treating genetic diseases and marks Danaher's first Beacon Project with a Chinese biotech firm.","og_url":"https:\/\/flcube.com\/?p=37449","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-16T08:46:29+00:00","article_modified_time":"2025-07-16T08:46:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1609.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37449#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37449"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System","datePublished":"2025-07-16T08:46:29+00:00","dateModified":"2025-07-16T08:46:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37449"},"wordCount":177,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37449#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1609.webp","keywords":["CorrectSequence Therapeutics","Cytiva","Danaher","Gene therapy","NYSE: DHR"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37449#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37449","url":"https:\/\/flcube.com\/?p=37449","name":"Danaher's Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37449#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37449#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1609.webp","datePublished":"2025-07-16T08:46:29+00:00","dateModified":"2025-07-16T08:46:30+00:00","description":"US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between its unit Cytiva and Shanghai-based gene editing technology provider CorrectSequence Therapeutics. Together, they are developing an innovative process solution for gene therapy using lipid nanoparticle (LNP) delivery systems. This partnership aims to drive breakthroughs in treating genetic diseases and marks Danaher's first Beacon Project with a Chinese biotech firm.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37449#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37449"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37449#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1609.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1609.webp","width":1080,"height":608,"caption":"Danaher's Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37449#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1609.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37449"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37449\/revisions"}],"predecessor-version":[{"id":37451,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37449\/revisions\/37451"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37450"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}